Compare ADMA Biologics Inc (ADMA) vs Ambarella Inc (AMBA) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Ambarella (AMBA) trades at $79.73, up 1.75% with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant $800M+ long-term edge AI agreement with Hanwha. Revenue grew 16.9% year-over-year in Q1 2027 to $100.4M, though the company remains unprofitable with a -17.18% net income margin. Analyst sentiment is strongly positive with 58% buy ratings and a $108.67 consensus price target representing 36% upside potential.

Ambarella presents a compelling growth story in edge AI with strong analyst support and recent business momentum, but faces execution risks in transitioning to profitability. The stock's current valuation at 8.47x sales appears justified given the company's positioning in the rapidly expanding physical AI market, though investors should monitor progress toward sustainable profitability and competitive pressures in the semiconductor space.